Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 967920, 6 pages
http://dx.doi.org/10.1155/2009/967920
Review Article

Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer

1Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
2State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, New Territories, Hong Kong

Received 1 December 2008; Accepted 30 January 2009

Academic Editor: Daniel Chua

Copyright © 2009 Herbert H. Loong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC) has expanded the armamentarium against this disease. This paper will review the historical progress and recent clinical developments of anti-EGFR therapies in the treatment of metastatic CRC. Novel strategies of targeting the EGFR pathway to improve efficacy as well as ongoing research in identifying specific molecular predictors of response will be discussed.